SSHPF yields 926.35% · JNJ yields 2.13%● Live data
📍 SSHPF pulled ahead of the other in Year 1
Combined, SSHPF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SSHPF + JNJ for your $10,000?
Vow ASA, together with its subsidiaries, produces, delivers, and maintains systems for processing and purifying wastewater, food waste, solid waste, and bio sludge in Norway, France, Poland, the United States, Canada, and Italy. It operates in three segments: Projects Cruise, Aftersales, and Landbased. The Projects Cruise segment delivers ship systems to shipyards for newbuild constructions, which include advanced wastewater purification, waste management, and food waste processing; advanced systems to shipowners for ships; and systems for aquaculture sludge treatment. The Aftersales segment provides spare parts and consumables; chemicals; and tailor-made service and maintenance programs. The Landbased segment offers Biogreen, a patented pyrolysis process for converting biomass, plastics, and waste into energy; Safesteril, a patented sterilisation process for food and pharmaceutical ingredients; and industrial robotics solutions, including robotic systems for waste recycling processes. The company serves cruise, aquaculture, and landbased industries, as well as utilities. It has a strategic partnership agreement with Repsol, S.A. to explore applications and solutions to produce clean and renewable energy for CO2 emission reduction. The company was formerly known as Scanship Holding ASA and changed its name to VOW ASA in January 2020. Vow ASA was incorporated in 2011 and is headquartered in Lysaker, Norway.
Full SSHPF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.